Cetuximab and Vemurafenib Plus FOLFIRI for BRAF V600E Mutated Advanced Colorectal Cancer (IMPROVEMENT)

Colorectal Cancer Clinical Trial

Official title:

Cetuximab and Vemurafenib Plus FOLFIRI for BRAF V600E Mutated Advanced Colorectal Cancer (IMPROVEMENT): A Single-arm Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03727763
• Other study ID #: IMPROVEMENT
• Status: Recruiting
• Phase: Phase 2
• Start date: October 8, 2018
• Est. completion date: December 31, 2022

Study information

• Verified date: August 2021
• Source: Shanghai Changzheng Hospital
• Contact: Yuan-Sheng Zang, Prof
• Phone: +8613816584620
• Email: doctorzangys[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This clinical trial aims to evaluate the efficacy, safety of FOLFIRI with vemurafenib and cetuximab in Advanced Colorectal Cancer Patients with BRAF V600E mutation.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: December 31, 2022
• Est. primary completion date: December 1, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Patients have histologically or cytologically confirmed advanced or recurrent CRC;

• Patients with BRAV V600E mutation/KRAS WT based on the NGS or ARMS-PCR detection of tumor tissue;

• Patients have measurable disease as defined by RECIST 1.1 as determined by investigator;

• Patient with a history of radiotherapy at least 3 months before on the day of providing consent, but the measurable lesion should not be within the scope of radiotherapy;

• Patients without a history of receiving vemurafenib or cetuximab;

• Patients with age of 18-75yr;

• Patients with a performance status of 0,1or 2 on the Eastern Cooperative Oncology Group.;

• Patients with Life expectancy of more than 12 weeks;

• Patients must have the ability to understand and sign the written informed consent voluntarily;

• Female of childbearing potential who are negative in a pregnancy test within 14 days before enrollment. Both male and female patients should agree to use an adequate method of contraception (total abstinence, an intrauterine device or hormone releasing system, an contraceptive implant and an oral contraceptive) starting with the first dose of study therapy through 120 days after the last dose of study therapy. Duration will be determined when the subject is assigned to treatment.

Exclusion Criteria:

• Patients with KRAS/NRAS mutation;

• Patients with major surgery or severe trauma within 4 weeks before the first medication;

• Patients with hypersensitivity to the components in the study protocol;;

• Patients who are ready to give birth or are pregnant.?

• Patients with brain metastases ?

• Bone marrow, liver and kidney function did not meet the requirements of chemotherapy as follows:

• Neutrophil count<1,500/mm3;

• Platelet count <80,000/mm3;

• Total bilirubin >1.5-times the upper limit of normal;

• ALT/AST>2.5-times the upper limit of normal for patients without liver metastases; (5.0-times the upper limit of normal for patients without liver metastases)

• Creatinine >1.5-times the upper limit of normal;

• Patients with cancers other than advanced colorectal cancer within five years prior to the start of treatment in this study. Cervical carcinoma in situ, cured basal cell carcinoma and bladder epithelial tumor were excluded;;

• Patients without legal capacity or limited civil capacity;

Related Conditions & MeSH terms

• Colorectal Cancer
• Colorectal Neoplasms

Intervention

Drug:
• Vemurafenib
960mg po bid
• Cetuximab
500mg/m2 iv gtt (14 days per course)

Locations

Country	Name	City	State
China	Shanghai Changzheng Hospital	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Shanghai Changzheng Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Objective Response Rate(ORR)	Evaluation of tumor burden based on RECIST criteria every 3 cycles(each cycle is 14 days), ORR is the proportion of patients with reduction in tumor burden of a predefined amount, including complete response and partial response.	up to 55 months
Secondary	Disease Control Rate (DCR)	Evaluation of tumor burden based on RECIST criteria every 3 cycles(each cycle is 14 days), and DCR is the proportion of patients with reduction in tumor burden of a predefined amount, including complete response, partial response and stable disease	up to 55 months
Secondary	Progression-free survival	Evaluation of tumor burden based on RECIST criteria until first documented progress through study completion, an average of 6 weeks	Time from treatment beginning until the date of first documented progression, assessed up to 55 months
Secondary	Overall survival	From date of treatment beginning until the date of death from any cause, through study completion, an average of 6 weeks	Time from treatment beginning until date of death from any cause, assessed up to 55 months
Secondary	adverse events	Incidence of Treatment-related adverse Events	Through study completion, an average of 4 weeks